RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). Other Scholarly Work

cited authors

  • Gilbert, MR; Wang, M; Aldape, KD; Stupp, R; Hegi, M; Jaeckle, KA; Armstrong, TS; Wefel, JS; Won, M; Blumenthal, DT; Mahajan, A; Schultz, CJ; Erridge, SC; Brown, PD; Chakravarti, A; Curran, WJ; Mehta, MP

sustainable development goals

authors

publication date

  • May 20, 2011

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

WoS ID

  • 000208880301222

Digital Object Identifier (DOI)

volume

  • 29

issue

  • 15

international collaboration

  • true